Br J Rheumatol. 1992 Apr;31(4):253-8.

Long-term second-line treatment: a prospective drug survival study.

Wijnands MJ, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LB, van Riel PL.

Source

Department of Rheumatology, University Hospital Nijmegen, The Netherlands.

Abstract

The long-term use of second-line antirheumatic drugs was prospectively studied in a consecutive sample of 245 patients with recently diagnosed rheumatoid arthritis. A survival analysis was done in which treatment termination due to side-effects and to insufficient therapeutic effect were used as index causes. Cumulative drug 'survival' of aurothioglucose with treatment termination due to toxicity was significantly less compared with hydroxychloroquine. With regard to lack of efficacy as index cause, the administration time of hydroxychloroquine was significantly less than that of either aurothioglucose or sulphasalazine. Treatment termination due to lack of efficacy or combined insufficient therapeutic response and toxicity proved to be influenced by the initial disease activity and by the rank order of prescription.

PMID:: 1348198; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

HighWire Press - PDF

Medical

Molecular Biology Databases

Libraries

LinkOut Holdings

Supplemental Content

Related citations

A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs. [Pharm World Sci. 1993]
A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs.
Wijnands MJ, Van 't Hof MA, Van Leeuwen MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL. Pharm World Sci. 1993 Oct 15; 15(5):203-7.
A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. [Ann Rheum Dis. 1989]
A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.
Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. Ann Rheum Dis. 1989 May; 48(5):389-95.
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. [Ann Rheum Dis. 2000]
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.
van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, Brus HL, van Albada-Kuipers GA, Heurkens AH, ter Borg EJ, et al. Ann Rheum Dis. 2000 Jun; 59(6):468-77.
Review Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine. [Curr Opin Rheumatol. 1994]
Review Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.
Girgis L, Conaghan PG, Brooks P. Curr Opin Rheumatol. 1994 May; 6(3):252-61.
Review Disease-modifying drugs for progressive rheumatoid arthritis. [Mayo Clin Proc. 1980]
Review Disease-modifying drugs for progressive rheumatoid arthritis.
Bunch TW, O'Duffy JD. Mayo Clin Proc. 1980 Mar; 55(3):161-79.

See reviews... See all...

Cited by 9 PubMed Central articles

Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. [Ann Rheum Dis. 2010]
Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis.
Farragher TM, Lunt M, Fu B, Bunn D, Symmons DP. Ann Rheum Dis. 2010 Apr; 69(4):689-95. Epub 2009 Oct 26.
Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. [J Rheumatol. 2008]
Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH. J Rheumatol. 2008 Sep; 35(9):1737-44. Epub 2008 Jul 15.
Rheumatologists, take heart! We may be doing something right. [Arthritis Res Ther. 2008]
Rheumatologists, take heart! We may be doing something right.
van Vollenhoven RF. Arthritis Res Ther. 2008; 10(2):105. Epub 2008 Mar 7.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Long-term second-line treatment: a prospective drug survival study.
Long-term second-line treatment: a prospective drug survival study.
Br J Rheumatol. 1992 Apr ;31(4):253-8.

PubMed
A randomized trial comparing aerobic exercise and resistance exercise with a hea...
A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST).
JAMA. 1997 Jan 1 ;277(1):25-31.

PubMed
Crystal-induced endogenous pyrogen production. A further look at gouty inflammat...
Crystal-induced endogenous pyrogen production. A further look at gouty inflammation.
Arthritis Rheum. 1985 Sep ;28(9):1039-46.

PubMed
Gait asymmetry in patients with limb-length inequality.
Gait asymmetry in patients with limb-length inequality.
J Pediatr Orthop. 1996 Mar-Apr ;16(2):144-50.

PubMed
Mannose binding protein gene mutations associated with unusual and severe infect...
Mannose binding protein gene mutations associated with unusual and severe infections in adults.
Lancet. 1995 Apr 8 ;345(8954):886-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Long-term second-line treatment: a prospective drug survival study.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Libraries

Supplemental Content

Related citations

Cited by 9 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information